Lakewood, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) ("KRTL" or the "Company") today announced that its wholly owned subsidiaries, KRTL International Corp. and KRTL Biotech Inc., have executed a definitive strategic partnership agreement with CENTRO DE INVESTIGACIONES QUIMICAS, S.R.L. ("CIQ") for the continued development and commercialization of the RAYEL platform.
The agreement marks an important transition for RAYEL. What began under a Memorandum of Understanding now moves into a binding framework designed to support U.S. commercialization, manufacturing evaluation, strategic partnerships, regulatory coordination, capital development and additional potential applications for the platform.
For KRTL, the timing is significant. The Company has been building the pieces around RAYEL - strengthening its U.S. regulatory and pharmaceutical/API capabilities, organizing the platform’s technical and commercial record, developing potential partner pathways and opening discussions with universities regarding potential research collaboration.
KRTL Holding Group management stated: “This agreement brings together work that has been developing on several fronts. We have CIQ’s scientific and technical foundation, a defined U.S. commercialization strategy, growing regulatory and API expertise through KRTL Biotech, and active discussions with universities. We can now begin bringing those pieces together around RAYEL and evaluating where the platform has the strongest opportunity to advance.”
The Platform and the Path
Under the agreement, KRTL will lead the U.S. commercialization pathway for RAYEL, while CIQ continues its scientific and technical role. The parties will coordinate strategy and make material project decisions together.
KRTL and CIQ are evaluating multiple potential uses and commercial pathways for RAYEL.
The platform has a documented beverage-facing TTB pathway for its documented product scope, while the parties are also evaluating how RAYEL could be developed across additional pharmaceutical/API-oriented and other potential applications.
Rather than building RAYEL around a single prospective market, KRTL intends to evaluate where the platform, its scientific record and future research may have the strongest commercial fit.
The Opportunity Around RAYEL
That strategy is taking shape against a growing global market for plant-derived extracts.
MarketsandMarkets estimates the global plant extracts market at approximately $47.54 billion in 2025 and projects it to reach $85.28 billion by 2030, representing a 12.4% compound annual growth rate. The market spans applications including food and beverages, pharmaceuticals, dietary supplements and cosmetics. Source: MarketsandMarkets
KRTL has been working to build the capabilities needed to evaluate RAYEL within that broader environment.
Through KRTL Biotech, the Company engaged Justin Abril as President-Designate and Strategic Regulatory & API Consultant, adding experience in regulatory strategy, pharmaceutical/API development planning, API/CMC documentation, controlled-substance compliance planning, import/export pathway review and partner diligence.
KRTL is also in active discussions with universities regarding potential research collaboration related to RAYEL, creating another potential avenue for scientific and technical development around the platform.
Put together, the strategy is becoming clearer: CIQ provides the scientific and technical foundation; KRTL is building the commercial, regulatory, research and partner-development infrastructure around it; and the definitive agreement provides the framework for those efforts to move forward together.
What Comes Next
The focus now turns to translating that framework into qualified opportunities.
KRTL and CIQ will continue developing the RAYEL technical and commercial record while evaluating research, manufacturing, strategic and commercial relationships in the United States. As individual opportunities mature, they can move into project-specific agreements appropriate to the particular pathway.
KRTL management added: “Signing the agreement is a milestone, but what matters now is what we build from it. Our focus is getting RAYEL in front of the right researchers, technical groups, manufacturers and commercial partners and allowing the science, the documentation and the market opportunity to guide where we go next.”
Any regulated manufacturing, controlled-substance handling, testing, importation, formulation, pharmaceutical/API development or distribution would be performed through appropriately qualified and authorized external parties.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. (OTC: KRTL) operates through specialized subsidiaries focused on life sciences, international project development, healthcare and related emerging commercial opportunities.
KRTL Biotech Inc. supports life-sciences platform development, regulatory and pharmaceutical strategy, partner coordination and commercialization. KRTL International Corp. serves as the Group’s international, federal-facing and cross-border project-development and partnering platform.
KRTL Holding Group: www.krtlholding.com
KRTL International: www.krtl-icc.com
Contact: info@krtlholding.com
Forward-Looking Statements
This press release contains forward-looking statements regarding RAYEL development, potential university and research collaborations, commercialization, manufacturing evaluation, pharmaceutical/API-oriented and other potential applications, strategic partnerships, regulatory pathways, financing and future commercial opportunities. Such statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.
RAYEL remains subject to technical validation, documentation, partner and institutional diligence, financing considerations, applicable regulatory requirements and future agreements. Evaluation of pharmaceutical/API-oriented, alkaloid-related, whole-extract or other regulated pathways does not mean that RAYEL has been approved or authorized for those uses. Any regulated activities would require the applicable licenses, registrations, approvals and appropriately qualified external parties.
The plant-extract market figures referenced above are third-party industry estimates from MarketsandMarkets and describe the broader global plant-extract industry. They are not estimates of RAYEL’s addressable market, future revenues, valuation or expected market share.
Discussions with universities and other prospective research, manufacturing, strategic or commercial partners remain subject to further diligence and definitive agreements where applicable. The execution of the CIQ agreement does not represent FDA approval, DEA authorization, secured financing or commercial launch.
